Gene therapies continue to be delivered using adeno-associated viruses (AAV), which means the essential issue of overexpression hasn't been adequately addressed

Gene therapies continue to be delivered using adeno-associated viruses (AAV), which means the essential issue of overexpression hasn't been adequately addressed. This impending clinical trial could very likely result in robust immune responses, potentially necessitating patients to take immunosuppressive drugs for the rest of their lives.